Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs. 29541216 2018
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. 28951457 2017
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR. 26365186 2015
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer. 26160848 2015
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). 24670642 2014
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times. 24025253 2013
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Colon cancers from 2008 to 2012 tested by pyrosequencing for BRAF V600E mutation were selected. 23650027 2013
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramatic improvement and other areas showing stable disease over a 7-month period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer. 23792568 2013
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Female patients and older group harbored a higher KRAS mutation (P = 0.018 and P = 0.031, respectively); BRAF (V600E) mutation showed a higher frequency in colon cancer and poor differentiation tumors (P = 0.020 and P = 0.030, respectively); proximal tumors appeared a higher PIK3CA mutation (P<0.001) and distant metastatic tumors shared a higher NRAS mutation (P = 0.010). 24339949 2013
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers with both vemurafenib and EGFR inhibitors is worth clinical evaluation. 23074264 2012
Malignant tumor of colon
CUI: C0007102
Disease: Malignant tumor of colon
0.100 GeneticVariation BEFREE Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors. 22281684 2012